421 related articles for article (PubMed ID: 33934171)
1. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer.
Lee MW; Jeon SK; Paik WH; Yoon JH; Joo I; Lee JM; Lee SH
J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):735-745. PubMed ID: 38332658
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
4. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
5. Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer.
Nakano O; Kawai H; Kobayashi T; Kohisa J; Ikarashi S; Hayashi K; Yokoyama J; Terai S
Cancer Med; 2021 Jul; 10(13):4291-4301. PubMed ID: 33993635
[TBL] [Abstract][Full Text] [Related]
6. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
7. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
8. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study.
Suzuki Y; Saito K; Nakai Y; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Takahara N; Tateishi R; Fujishiro M
Support Care Cancer; 2023 Mar; 31(3):197. PubMed ID: 36862196
[TBL] [Abstract][Full Text] [Related]
9. Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Ishizaki A; Okuwaki K; Kida M; Imaizumi H; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Watanabe M; Kurosu T; Ishizaki J; Kusano C
Intern Med; 2023 Oct; 62(19):2783-2793. PubMed ID: 36792197
[TBL] [Abstract][Full Text] [Related]
10. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.
Sohal DPS; Boutin RD; Lenchik L; Kim J; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Chang VT
J Gastrointest Surg; 2024 Mar; 28(3):232-235. PubMed ID: 38445914
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patients.
Sevgilioglu ZE; Evrimler S; Iscan G; Kayikcioglu E; Sengul SS; Cetin B
Acta Radiol; 2023 Nov; 64(11):2849-2857. PubMed ID: 37661639
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer - A multicenter population-based cohort study.
Maurits JSF; Sedelaar JPM; Mulders PFA; Aben KKH; Kiemeney LALM; Vrieling A
Clin Nutr; 2022 Jan; 41(1):131-143. PubMed ID: 34872047
[TBL] [Abstract][Full Text] [Related]
14. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy.
Rom H; Tamir S; Van Vugt JLA; Berger Y; Perl G; Morgenstern S; Tovar A; Brenner B; Benchimol D; Kashtan H; Sadot E
Ann Surg Oncol; 2022 Mar; 29(3):1553-1563. PubMed ID: 34716836
[TBL] [Abstract][Full Text] [Related]
16. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract][Full Text] [Related]
17. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
Peng YC; Wu CH; Tien YW; Lu TP; Wang YH; Chen BB
Eur Radiol; 2021 Apr; 31(4):2472-2481. PubMed ID: 32974690
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Asama H; Ueno M; Kobayashi S; Fukushima T; Kawano K; Sano Y; Tanaka S; Nagashima S; Morimoto M; Ohira H; Maeda S
Pancreas; 2022 Feb; 51(2):148-152. PubMed ID: 35404889
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
Degens JHRJ; Sanders KJC; de Jong EEC; Groen HJM; Smit EF; Aerts JG; Schols AMWJ; Dingemans AC
Lung Cancer; 2019 Jul; 133():130-135. PubMed ID: 31200819
[TBL] [Abstract][Full Text] [Related]
20. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
